Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer

Molecular Cancer Therapeutics

Volumn 11, Issue 2, 2012, Pages 277-287

  Chen, Jing ^a,b   Wang, Jieqiong ^a   Lin, Lei ^a   He, Lijun ^a   Wu, Yuanyuan ^a   Zhang, Li ^a   Yi, Zhengfang ^a   Chen, Yihua ^a   Pang, Xiufeng ^a   Liu, Mingyao ^a,c  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CYCLIN D1; HEPARIN; JANUS KINASE 2; MATRIGEL; NITIDINE; PROTEIN BCL XL; STAT3 PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DNA BINDING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING; ZANTHOXYLUM;

ANIMALS; APOPTOSIS; BENZOPHENANTHRIDINES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863151419     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0648     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
3. Kitadai Y. Angiogenesis and lymphangiogenesis of gastric cancer. J Oncol 2010;2010:468725.
4. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010;60:222-43.
5. Yang S, Ngo VC, Lew GB, Chong LW, Lee SS, Ong WJ, et al. AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Mol Cancer Ther 2009;8:2537-45.
6. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005;24:5552-60. (Pubitemid 43119350)
7. Jung JE, Lee HG, Cho IH, Chung DH, Yoon SH, Yang YM, et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 2005;19:1296-8. (Pubitemid 41113728)
8. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-54. (Pubitemid 35177340)
9. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, et al. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 2006;12:20-8. (Pubitemid 43166171)
10. Gamero AM, Young HA, Wiltrout RH. Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer? Cancer Cell 2004;5:111-2. (Pubitemid 38283795)
11. Yu ZY, Huang R, Xiao H, Sun WF, Shan YJ, Wang B, et al. Fluacrypyrim, a novel STAT3 activation inhibitor, induces cell cycle arrest and apoptosis in cancer cells harboring constitutively-active STAT3. Int J Cancer 2010;127:1259-70.
12. Pathak AK, Bhutani M, Nair AS, Ahn KS, Chakraborty A, Kadara H, et al. Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res 2007;5:943-55. (Pubitemid 47416671)
13. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 2009;6:395-404.
14. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66:1022-37. (Pubitemid 36909859)
15. Hu J, Zhang WD, Liu RH, Zhang C, Shen YH, Li HL, et al. Benzophenanthridine alkaloids from Zanthoxylum nitidum (Roxb.) DC, and their analgesic and anti-inflammatory activities. Chem Biodivers 2006;3:990-5. (Pubitemid 44540931)
16. Iwasaki H, Okabe T, Takara K, Toda T, Shimatani M, Oku H. Tumor-selective cytotoxicity of benzo[c]phenanthridine derivatives from Toddalia asiatica Lam. Cancer Chemother Pharmacol 2010;65:719-26.
17. Xu Q, Li ZX, Ye ZM. [Nitidine chloride-induced apoptosis of human osteosarcoma cells and its mechanism]. Nan Fang Yi Ke Da Xue Xue Bao 2011;31:361-4.
18. van Dross RT, Sanders MM. Molecular characterization of recombinant Pneumocystis carinii topoisomerase I: differential interactions with human topoisomerase I poisons and pentamidine. Antimicrob Agents Chemother 2002;46:2145-54. (Pubitemid 34665909)
19. Tan GT, Pezzuto JM, Kinghorn AD, Hughes SH. Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. J Nat Prod 1991;54:143-54.
20. Moser C, Lang SA, Mori A, Hellerbrand C, Schlitt HJ, Geissler EK, et al. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma (HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer 2008;8:206.
21. Jung JE, Kim HS, Lee CS, Park DH, Kim YN, Lee MJ, et al. Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells. Carcinogenesis 2007;28:1780-7. (Pubitemid 47289042)
22. Pang X, Yi T, Yi Z, Cho SG, Qu W, Pinkaew D, et al. Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res 2009;69:518-25.
23. Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, et al. Acetyl-11-keto-beta- boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 2009;69:5893-900.
24. Pyun BJ, Choi S, Lee Y, Kim TW, Min JK, Kim Y, et al. Capsiate, a nonpungent capsaicin-like compound, inhibits angiogenesis and vascular permeability via a direct inhibition of Src kinase activity. Cancer Res 2008;68:227-35. (Pubitemid 351380124)
25. Ziche M, Morbidelli L. The corneal pocket assay. Methods Mol Biol 2009;467:319-29.
26. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 2006;281:5612-22. (Pubitemid 43847658)
27. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003;171:3863-71. (Pubitemid 37254592)
28. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995;269:81-3.
29. Ye SK, Agata Y, Lee HC, Kurooka H, Kitamura T, Shimizu A, et al. The IL-7 receptor controls the accessibility of the TCRgamma locus by Stat5 and histone acetylation. Immunity 2001;15:813-23. (Pubitemid 34008508)
30. Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, et al. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 2010;70:1951-9.
31. Kim DY, Cha ST, Ahn DH, Kang HY, Kwon CI, Ko KH, et al. STAT3 expression in gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol 2009;24:646-51.
32. Jackson CB, Giraud AS. STAT3 as a prognostic marker in human gastric cancer. J Gastroenterol Hepatol 2009;24:505-7.
33. Yang C, Schwab JH, Schoenfeld AJ, Hornicek FJ, Wood KB, Nielsen GP, et al. A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Mol Cancer Ther 2009;8:2597-605.
34. Lee HJ, Seo NJ, Jeong SJ, Park Y, Jung DB, Koh W, et al. Oral administration of Penta-O-galloyl-{beta}-D-glucose Suppresses Triple-negative Breast Cancer Xenograft Growth and Metastasis in Strong Association with JAK1-STAT3 Inhibition. Carcinogenesis 2011;32:804-11.
35. Pandey MK, Sung B, Aggarwal BB. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int J Cancer 2010;127:282-92.
36. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49. (Pubitemid 351656458)
37. Reinacher-Schick A, Pohl M, Schmiegel W. Drug insight: antiangiogenic therapies for gastrointestinal cancers-focus on monoclonal antibodies. Nat Clin Pract Gastroenterol Hepatol 2008;5:250-67. (Pubitemid 351637911)
38. Zhu BH, Chen HY, Zhan WH, Wang CY, Cai SR, Wang Z, et al. (-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer. World J Gastroenterol 2011;17:2315-25.
39. Zhu BH, Zhan WH, Li ZR, Wang Z, He YL, Peng JS, et al. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J Gastroenterol 2007;13:1162-9. (Pubitemid 46592955)
40. Chen Z, Han ZC. STAT3: a critical transcription activator in angiogenesis. Med Res Rev 2008;28:185-200. (Pubitemid 351281185)
41. Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q, et al. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 2008;7:2192-202.
42. Ren Z, Schaefer TS. ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner. J Biol Chem 2002;277:38486-93. (Pubitemid 35154707)
43. Schreiner SJ, Schiavone AP, Smithgall TE. Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem 2002;277:45680-7. (Pubitemid 36159180)
44. Zhang X, Song Y, Wu Y, Dong Y, Lai L, Zhang J, et al. Indirubin inhibits tumor growth by anti-tumor angiogenesis through blocking VEGFR2 mediated JAK/STAT3 signaling in endothelial cell. Int J Cancer 2011;129:2502-11.
45. Dong Y, Lu B, Zhang X, Zhang J, Lai L, Li D, et al. Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis 2010;31:2097-104.
46. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2:740-9.
47. Finucane DM, Bossy-Wetzel E, Waterhouse NJ, Cotter TG, Green DR. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J Biol Chem 1999;274:2225-33.
48. Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg 2004;198:83-90. (Pubitemid 38201092)
49. Varin E, Denoyelle C, Brotin E, Meryet-Figuiere M, Giffard F, Abeilard E, et al. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis 2010;31:984-93.
50. Brotin E, Meryet-Figuiere M, Simonin K, Duval RE, Villedieu M, Leroy-Dudal J, et al. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int J Cancer 2010;126:885-95.